JP2017523781A5 - - Google Patents

Download PDF

Info

Publication number
JP2017523781A5
JP2017523781A5 JP2017505552A JP2017505552A JP2017523781A5 JP 2017523781 A5 JP2017523781 A5 JP 2017523781A5 JP 2017505552 A JP2017505552 A JP 2017505552A JP 2017505552 A JP2017505552 A JP 2017505552A JP 2017523781 A5 JP2017523781 A5 JP 2017523781A5
Authority
JP
Japan
Prior art keywords
aptamer
nucleic acid
seq
dimer
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017505552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017523781A (ja
JP6680760B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/043162 external-priority patent/WO2016019270A1/en
Publication of JP2017523781A publication Critical patent/JP2017523781A/ja
Publication of JP2017523781A5 publication Critical patent/JP2017523781A5/ja
Application granted granted Critical
Publication of JP6680760B2 publication Critical patent/JP6680760B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017505552A 2014-07-31 2015-07-31 アンタゴニストic pd−1アプタマー及びその癌治療関連用途への応用 Expired - Fee Related JP6680760B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462031427P 2014-07-31 2014-07-31
US62/031,427 2014-07-31
PCT/US2015/043162 WO2016019270A1 (en) 2014-07-31 2015-07-31 An antagonistic pd-1 aptamer and its applications in cancer therapy related applications

Publications (3)

Publication Number Publication Date
JP2017523781A JP2017523781A (ja) 2017-08-24
JP2017523781A5 true JP2017523781A5 (Direct) 2018-09-13
JP6680760B2 JP6680760B2 (ja) 2020-04-15

Family

ID=55218360

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017505552A Expired - Fee Related JP6680760B2 (ja) 2014-07-31 2015-07-31 アンタゴニストic pd−1アプタマー及びその癌治療関連用途への応用

Country Status (8)

Country Link
US (1) US10329570B2 (Direct)
EP (1) EP3174985A4 (Direct)
JP (1) JP6680760B2 (Direct)
KR (1) KR20170055474A (Direct)
CN (1) CN107002083A (Direct)
CA (1) CA2956718A1 (Direct)
TW (1) TWI703214B (Direct)
WO (1) WO2016019270A1 (Direct)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108136025B (zh) 2015-07-16 2022-09-06 比奥克斯塞尔医疗股份有限公司 一种使用免疫调节治疗癌症的新颖方法
WO2017143150A1 (en) 2016-02-19 2017-08-24 City Of Hope Bi-specific aptamer
US20190233824A1 (en) * 2016-09-06 2019-08-01 The Methodist Hospital System Pd-1 specific aptamers
JP7560821B2 (ja) * 2016-09-16 2024-10-03 デューク ユニバーシティ フォン・ビルブラント因子(vwf)標的薬剤およびそれを用いる方法
CN107794267B (zh) * 2017-03-14 2021-03-26 湖南大学 一种靶向pd1-pdl1的双特异性核酸适体及其衍生物
US11427826B2 (en) 2017-08-11 2022-08-30 City of Hopw RNA aptamers against transferrin receptor (TfR)
US11007211B2 (en) 2018-01-07 2021-05-18 City Of Hope CCR7 aptamers and uses thereof
EP3683310A1 (en) 2019-01-21 2020-07-22 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamer and use of the aptamer in the diagnosis and treatment of cancer
CN111154765B (zh) * 2019-12-30 2023-08-01 广西医科大学 T细胞免疫检查点pd-1的适配体筛选、鉴定方法及抗肿瘤应用
JP7181325B2 (ja) 2020-03-03 2022-11-30 アレイ バイオファーマ インコーポレイテッド がんを処置するための方法
CN111593053B (zh) * 2020-05-27 2022-02-15 武汉大学 识别人程序性死亡受体1的dna适配体及方法和应用
WO2023070132A1 (en) * 2021-10-22 2023-04-27 Ohio State Innovation Foundation Immunotherapies for the treatment of cancer

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
WO1997031012A1 (en) * 1996-02-22 1997-08-28 The Regents Of The University Of Michigan Gene specific universal mammalian sequence-tagged sites
WO2001077384A2 (de) * 2000-04-07 2001-10-18 Epigenomics Ag DETEKTION VON SNPs UND CYTOSIN-METHYLIERUNGEN
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US8039443B2 (en) * 2002-11-21 2011-10-18 Archemix Corporation Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
EP1581548A4 (en) * 2002-11-21 2008-04-23 Archemix Corp MULTIVALENT APTAMER THERAPEUTIC WITH IMPROVED PHARMACODYNAMIC PROPERTIES AND METHOD FOR THE PRODUCTION AND USE THEREOF
AU2004232848A1 (en) * 2003-04-21 2004-11-04 Archemix Corp. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
ME00016B (me) * 2005-08-26 2010-06-10 Aptameri koji vezuje trombin sa visokim afininitetom
US8143230B2 (en) * 2006-05-05 2012-03-27 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of PCSK9
US8835111B2 (en) * 2009-03-12 2014-09-16 Brainco Biopharma S.L. Genotyping tool for improving the prognostic and clinical management of MS patients
US20130209514A1 (en) * 2009-06-09 2013-08-15 Eli Gilboa Aptamer-targeted costimulatory ligand aptamer
EP2354247A1 (en) * 2010-02-11 2011-08-10 Academisch Medisch Centrum bij de Universiteit van Amsterdam Means and methods for typing a sample for rheumatoid arthritis or spondyloarthritis
US20140148503A1 (en) * 2011-07-20 2014-05-29 University Of Iowa Research Foundation Nucleic acid aptamers
MX356581B (es) * 2012-02-16 2018-06-05 Syngenta Participations Ag Proteinas pesticidas modificadas.
US20150086584A1 (en) 2012-03-22 2015-03-26 University Of Miami Multi-specific binding agents
US10058623B2 (en) * 2012-05-16 2018-08-28 Translate Bio Ma, Inc. Compositions and methods for modulating UTRN expression
US9958448B2 (en) * 2012-10-23 2018-05-01 Caris Life Sciences Switzerland Holdings Gmbh Aptamers and uses thereof
CN104903450A (zh) * 2012-11-05 2015-09-09 普隆奈治疗公司 寡核苷酸癌症疗法的给药和施用
CA2892490A1 (en) * 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
ES3047792T3 (en) * 2014-07-14 2025-12-04 Univ California Crispr/cas transcriptional modulation

Similar Documents

Publication Publication Date Title
JP2017523781A5 (Direct)
Zhou et al. Engineering and delivery of cGAS-STING immunomodulators for the immunotherapy of cancer and autoimmune diseases
Luo et al. Biodegradable multiblock poly [N-(2-hydroxypropyl) methacrylamide] via reversible addition− fragmentation chain transfer polymerization and click chemistry
Li et al. Current drug research on PEGylation with small molecular agents
CY1123978T1 (el) Σταθερα και διαλυτα αντισωματα που αναστελλουν ton tnf
JP2016521688A5 (Direct)
CN102920649B (zh) 载药纳米胶束及其制备方法和应用
JP2013515745A5 (Direct)
JP2019513118A5 (Direct)
JP2018015005A5 (Direct)
JP2012255007A5 (Direct)
Ji et al. Development of self-assembled multi-arm polyrotaxanes nanocarriers for systemic plasmid delivery in vivo
JP2016153410A5 (Direct)
JP2016502515A5 (Direct)
FI3430027T3 (fi) Peptidi käytettäväksi ei-pienisoluisen keuhkosyövän ja pienisoluisen keuhkosyövän hoidossa
JP2014526881A5 (Direct)
JP2015519313A5 (Direct)
JP2014520120A5 (Direct)
JP2019531093A5 (Direct)
JP2018522563A5 (Direct)
JP2012509902A5 (Direct)
JP2017528444A5 (Direct)
JP2017501130A5 (Direct)
JP2013513377A5 (Direct)
RU2019102009A (ru) Специфические антитела к pd-l1 и способы их применения